Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease.
about
New Immunosuppressive Therapies in Uveitis TreatmentAnti-TNF-alpha therapy and systemic vasculitis.Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet uveitis.Behçet's Uveitis.Biological treatments in Behçet's disease: beyond anti-TNF therapy.An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.Efficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient data.The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.Pharmacotherapy for uveitis: current management and emerging therapy.Behcet's Syndrome.Systemic therapies for inflammatory eye disease: past, present and futureLocal therapies for inflammatory eye disease in translation: past, present and futureCorrelation between Ocular Manifestations and Their Complications as Opposed to Visual Acuity and Treatment in Behcet's Disease.New Evidence-Based Treatment Approach in Behçet's Disease.Clinical trials in noninfectious uveitisEfficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patientsAdalimumab in the therapy of uveitis in childhoodTumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.Biologic therapies for inflammatory eye disease.Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behçet Disease.Standard and novel therapeutic approaches to Behçet's disease.Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases.Biologic agents in the management of inflammatory eye diseases.Managing Behçet's disease: An update on current and emerging treatment options.Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.Update on the diagnosis and management of Behçet's disease.Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease.Infliximab for the treatment of active scleritis.More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial.Evidence-based practice in Behçet's disease: identifying areas of unmet need for 2014.Behçet's disease: an algorithmic approach to its treatment.Update on the use of systemic biologic agents in the treatment of noninfectious uveitis.A review and update on orphan drugs for the treatment of noninfectious uveitisClinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Update on the therapy of Behçet disease.Clinical experience with adalimumab in the treatment of ocular Behçet disease.Biological agents for the treatment of uveitis.Light on the horizont: biologicals in Behçet uveitis.The role of biologic agents in the management of non-infectious uveitis.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.
P2860
Q26798201-973B5D68-A6CD-4F3B-BCF5-0EE841BBA2BFQ27687590-CC3588A8-B063-462E-9E58-9E2A46B35E12Q30844158-C46921E7-0C68-4F1D-93F1-358AC9CF7C70Q33559788-C6C27316-F2EF-4212-B227-07A9A6D37CBFQ33908217-F4F54327-1BC2-456E-82D4-752C62CFF6A9Q33910781-77DA019B-77E4-4FEA-A055-327CD69C4BE9Q34142185-C077E2D2-9539-4AF3-A2C4-364A98F0B884Q34220221-E74DA6E3-1C36-49DC-8948-9535B457F04AQ34274075-C8D1C0F1-8278-4690-B467-B624F1BF343EQ34311953-02F49C59-63D1-431D-BF4A-83E6B8F193A9Q34687332-66C186D5-34EF-49C0-9664-BB0AB0E144B8Q34892662-C8FC50EA-E234-4857-8E32-2B92521A201BQ35001001-FAA74679-51DF-4258-B4CB-E193A8737434Q35295186-1493BE31-3315-4AF2-B171-97EA12AF2C21Q35681664-63DCCA27-5223-469E-8D2E-37238BC209EEQ35699360-DB50E036-9DD1-44F6-B811-D9E1CB18596FQ35763157-C2737304-1FFD-47EC-951E-5496083F9E64Q36388536-29844CB9-833A-4DFA-B8F1-1853BBD4CB89Q36501675-31FDD714-51BD-4822-A4F1-1AFD5857B04DQ36731095-AAEDFAE6-7DE3-4A01-8E57-1E14434D1359Q36947032-18EC0F96-07E1-4846-8B7E-CAD920D707D1Q37174386-EA5BCAE5-0F93-48A4-B697-50F76DB0CDFDQ37208980-617C490C-E6F5-41DA-AA98-6F4ED673D3BCQ37230348-66684DC3-2577-4D80-A074-3258836D2147Q37299387-53C41890-D1ED-48DB-B792-9C13F454FCDEQ37301191-64137C38-9897-4F40-909E-5D67EED897ECQ37406600-1B98DC65-2A12-4208-BB4F-863E6AF35B80Q37407155-0EF5B4BA-CFFF-4384-973F-A6DB1C08EB9FQ37487110-0E9327BD-1BB5-40BD-8CD7-9FB6F08BF1C5Q37539557-D25606C1-B04C-4F58-936E-B9F54E6E8528Q37583633-93183FA6-FBB0-4483-BDB3-7C3AC92AE20BQ37600483-CB720797-974B-4258-9C86-760FEABCAF1BQ37632096-43E307A3-92F8-4A20-AB0B-29CD115DACB4Q37650221-1F230BE5-53F2-4A41-A22C-9F34CC1AE025Q37712230-B6F4A16F-246E-42C4-971D-12EE691FCF4BQ37756167-C7A91AD0-644B-445D-9D26-ED5DD7CEF686Q37984565-36D94EA4-D043-46AB-9C85-DD5F3284CDA1Q38004097-D794F052-9450-4224-9C48-0EC68D2E32DDQ38025152-D1C7C9D9-6BC5-4422-910C-3AFE142A5E4FQ38074446-2C0C4613-9A01-4E49-BA74-63F014F1436F
P2860
Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Infliximab for recurrent, sigh ...... n Adamantiades-Behçet disease.
@en
Infliximab for recurrent, sigh ...... n Adamantiades-Behçet disease.
@nl
type
label
Infliximab for recurrent, sigh ...... n Adamantiades-Behçet disease.
@en
Infliximab for recurrent, sigh ...... n Adamantiades-Behçet disease.
@nl
prefLabel
Infliximab for recurrent, sigh ...... n Adamantiades-Behçet disease.
@en
Infliximab for recurrent, sigh ...... n Adamantiades-Behçet disease.
@nl
P2093
P1476
Infliximab for recurrent, sigh ...... n Adamantiades-Behçet disease.
@en
P2093
Elezoglou A
Kaklamanis PH
Katsilambros N
Markomichelakis N
Papaefthimiou S
Sfikakis PP
Theodossiadis PG
P304
P356
10.7326/0003-4819-140-5-200403020-00025
P407
P577
2004-03-01T00:00:00Z